Research Analysts’ Recent Ratings Updates for Q32 Bio (QTTB)

A number of firms have modified their ratings and price targets on shares of Q32 Bio (NASDAQ: QTTB) recently:

• 10/12/2026 – Q32 Bio is now covered by Leerink Partners. They set an “outperform” rating and a $40.00 price target on the stock.
• 10/1/2026 – Q32 Bio had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc..
• 9/28/2026 – Q32 Bio is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $29.00 price target on the stock.
• 9/28/2026 – Q32 Bio is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $29.00 price target on the stock.
• 9/16/2026 – Q32 Bio had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/7/2026 – Q32 Bio was upgraded by Mizuho to “strong-buy”.
• 8/24/2026 – Q32 Bio is now covered by Morgan Stanley. They set an “overweight” rating and a $34.00 price target on the stock.
• 8/21/2026 – Q32 Bio was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.

Insider Transactions at Q32 Bio

In related news, CEO Jodie Morrison sold 9,845 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total transaction of $163,033.20. Following the completion of the transaction, the chief executive officer directly owned 343,259 shares of the company’s stock, valued at $5,684,369.04. This represents a 2.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Lee Kalowski sold 3,972 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total transaction of $65,776.32. Following the transaction, the chief financial officer directly owned 138,471 shares of the company’s stock, valued at $2,293,079.76. This represents a 2.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 22,054 shares of company stock worth $320,397 over the last ninety days. 34.46% of the stock is currently owned by company insiders.

Q32 Bio is a clinical-stage biotechnology company focused on developing therapies designed to restore immune homeostasis and address diseases driven by immune dysregulation. The company’s approach targets pathways involved in the transforming growth factor beta superfamily, which plays a role in regulating inflammation, tissue repair and immune responses.

Q32 Bio’s lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to modulate immune activity through selective targeting of the activin receptor type IIA pathway.